 TRACON Pharmaceuticals Inc NASDAQ:TCON has announced a 35 million non-dilutive long-term debt facility with Runway Growth Capital LLC to support its ongoing pivotal ENVASARC trial to treat cancer and for general corporate purposes. The biopharma said that 10 million of the 35 million loan was funded upon closing, and the additional 25 million available may be funded upon achieving certain clinical milestones and at Runways discretion. 